Why Oscar Health Is Back on Investors’ Radar

Interest in Oscar Health (OSCR) has picked up after recent commentary highlighted 41.2% annual revenue growth over the last two years and better adjusted operating profits driven by efficiency and fixed cost leverage.

Despite solid interest around efficiency gains, the share price is still down, with a 30 day share price return showing a 6.29% decline and a 90 day share price return showing a 21.30% decline. At the same time, the 1 year total shareholder return of 10.67% and 3 year total shareholder return of about 9x suggest that longer term holders have seen much stronger results.

If Oscar Health’s move has caught your eye, this can be a good moment to see what else is setting the pace among healthcare related AI names with 37 healthcare AI stocks.

With revenue growing, efficiency improving, a recent share price pullback, and a roughly 19% gap to the current analyst price target, the key question is simple: is Oscar Health undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 16% Undervalued

With Oscar Health last closing at $12.97 and the most followed narrative pointing to a fair value of $15.40, the gap between price and expectations is clear and sets up a valuation story anchored in future earnings power and operational efficiency.

The company's substantial capital reserves ($5.4 billion in cash/investments, $579 million in excess capital at insurance subsidiaries), low leverage, and disciplined SG&A management provide ample liquidity and financial resilience, enhancing long-term earnings power and reducing solvency risk.

Want to see what kind of revenue build and margin shift needs to happen for that target to stack up? The narrative focuses on a steep earnings ramp, rising profitability, and a valuation multiple that ties all of those forecasts together.

Result: Fair Value of $15.40 (UNDERVALUED)

However, there are still clear pressure points, including higher claims costs in the ACA market and potential policy shifts around premium tax credits that could derail this earnings ramp.

Next Steps

With both risks and rewards in focus, sentiment on Oscar Health is clearly mixed. It may be useful to move quickly and test the numbers yourself with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Oscar Health is on your watchlist, do not stop there. Widen your search and let data driven shortlists surface opportunities you might otherwise miss.

• Target potential value plays by scanning companies that look mispriced on quality and fundamentals with 61 high quality undervalued stocks.
• Focus on resilience first by reviewing 70 resilient stocks with low risk scores that score well on stability and downside protection.
• Hunt for future standouts early by checking the screener containing 24 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.